Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 6 days · First seen 24 days ago · Last updated 19 days ago

Halozyme Therapeutics market performance

Overview

Halozyme Therapeutics reached a new 52-week high, with share prices hitting $109.10 and a market capitalization of $12.33 billion.

Financial analysts have responded with mixed but generally positive ratings. Leerink Partners upgraded the stock from ‘market perform’ to ‘outperform’ with a $110.00 target, and Wall Street Zen issued a ‘strong-buy’ rating. While institutions like UBS Group and Benchmark maintained ‘buy’ ratings, Morgan Stanley adjusted its price objective to $93.00. The consensus among nine analysts is a ‘Buy’ rating, despite three ‘Hold’ ratings and one ‘Sell’ rating, with an average target price of $91.20.

Entities

Nasdaq · Haleon plc · Halozyme Therapeutics, Inc. · Morgan Stanley · UBS Group

Timeline

19 days ago

[BUSINESS] 2 sources
Halozyme Therapeutics shares reach new 52-week high
Halozyme Therapeutics (HALO) reached a new 52-week high of $109.10, supported by several analyst upgrades and a market capitalization of $12.33 billion.
24 days ago

[BUSINESS] 3 sources
Haleon and Halozyme report corporate financial activities
Haleon plc announced results for a $1.34 billion tender offer of its 2027 senior notes, while Halozyme Therapeutics CEO Helen Torley sold 20,000 shares via a pre-arranged trading plan.

Sources

aijourn.com · mommygearest.com · seekingalpha.com · stocknews.com